Olavi Pelkonen
Impact in
- Pharmacology top 0.01%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
- Biochemistry top 0.2%
- Eicosanoids and Hypertension Pharmacology
Papers in
- Pharmacology 181
- Pharmacogenetics and Drug Metabolism 177
- Drug-Induced Hepatotoxicity and Protection 31
- Biochemistry 39
- Eicosanoids and Hypertension Pharmacology 28
- Co-authors
- Hannu RaunioMarkku PasanenJukka HakkolaMiia TurpeinenJanne HukkanenArja RautioNiilo T. KärkiD W Nebert
- Journals
- Biochemical Pharmacology (24 papers)European Journal of Clinical Pharmacology (11 papers)British Journal of Clinical Pharmacology (10 papers)Chemico-Biological Interactions (9 papers)Xenobiotica (8 papers)
- Partner nations
- FinlandUnited StatesUnited Kingdom
In The Last Decade
Olavi Pelkonen
289 papers receiving 12.5k citations
Hit Papers
Peers
Comparison fields: 5 of 168
- Pharmacology 6.4k
- Biochemistry 1.0k
- Cancer Research 1.9k
- Health, Toxicology and Mutagenesis 1.7k
- Oncology 2.8k
Countries citing papers authored by Olavi Pelkonen
This map shows the geographic impact of Olavi Pelkonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olavi Pelkonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olavi Pelkonen more than expected).
Fields of papers citing papers by Olavi Pelkonen
This network shows the impact of papers produced by Olavi Pelkonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olavi Pelkonen. The network helps show where Olavi Pelkonen may publish in the future.
Co-authors
The 25 scholars most cited alongside Olavi Pelkonen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2021 | 16 | |
| 3 | 2019 | 10 | |
| 4 | 2015 | 2 | |
| 5 | 2013 | 12 | |
| 6 | 2013 | 16 | |
| 7 | 2013 | 20 | |
| 8 | 2009 | 16 | |
| 9 | 2006 | 95 | |
| 10 | Induction and inhibition of cytochrome P-450* | 2004 | 1 |
| 11 | 2002 | 245 | |
| 12 | 2001 | 10 | |
| 13 | 1999 | 23 | |
| 14 | 1998 | 179 | |
| 15 | 1997 | 134 | |
| 16 | 1995 | 132 | |
| 17 | 1993 | 44 | |
| 18 | 1991 | 16 | |
| 19 | 1991 | 24 | |
| 20 | Characterization of benzo(a)pyrene hydroxylase of trout liver. | 1977 | 50 |
About Olavi Pelkonen
Olavi Pelkonen is a scholar working on Pharmacology, Biochemistry, Cancer Research, Clinical Biochemistry and Oncology, having authored 291 papers that have together received 13.2k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (177 papers), Drug Transport and Resistance Mechanisms (70 papers), Carcinogens and Genotoxicity Assessment (47 papers), Drug-Induced Hepatotoxicity and Protection (31 papers), Eicosanoids and Hypertension Pharmacology (28 papers), Toxic Organic Pollutants Impact (25 papers), Glutathione Transferases and Polymorphisms (24 papers) and Metabolism and Genetic Disorders (22 papers). The work is most often cited by research in Pharmacology (6.4k citations), Biochemistry (1.0k citations), Cancer Research (1.9k citations), Health, Toxicology and Mutagenesis (1.7k citations) and Oncology (2.8k citations). Olavi Pelkonen has collaborated with scholars based in Finland, United States and United Kingdom. Frequent co-authors include Hannu Raunio, Markku Pasanen, Jukka Hakkola, Miia Turpeinen, Janne Hukkanen, Arja Rautio, Niilo T. Kärki, D W Nebert, Alan R. Boobis and Ari Tolonen. Their work appears in journals such as Biochemical Pharmacology, European Journal of Clinical Pharmacology, British Journal of Clinical Pharmacology, Chemico-Biological Interactions and Xenobiotica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.